Biotechnology Clinical Trials This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the most recent publications within this specialty of the MedWorm directory.

PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual
Condition: HealthyInterventions: Drug: Pegylated rhEPO; Drug: EPIAO®Sponsors: Xiamen Amoytop Biotech Co., Ltd.; Xiamen Amoytop Biotech Co., Ltd.Recruiting - verified August 2012 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2013 Category: Research Source Type: clinical trials

HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
CHARLOTTESVILLE, Va., Feb. 21, 2013 /PRNewswire/ -- HemoShear LLC, a biotechnology research company and leading developer of human and animal cell-based systems for discovery and assessment of new drug compounds, will present three... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 21, 2013 Category: Pharmaceuticals Source Type: clinical trials

Oncolytics Biotech Inc. Announces Additional Positive REOLSYIN Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung
CALGARY, Feb. 8, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC) (NASDAQ: ONCY) today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 8, 2013 Category: Pharmaceuticals Source Type: clinical trials

PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
--New Data Demonstrate Potential for Long-Acting Subcutaneous Administration, Potentially Allowing Hemophilia Patients to Self-Administer Factor Vlla-CTP at Home Prophylactically-- WARSAW, Poland and NES-ZIONA, Israel, Feb. 6, 2013... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 6, 2013 Category: Pharmaceuticals Source Type: clinical trials

Amarantus BioScience Reports Statistical Significance Achieved for MANF Striatal Reinnervation in Neurorestoration Animal Model of Parkinson's Disease
SUNNYVALE, Calif., Feb. 4, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 4, 2013 Category: Pharmaceuticals Source Type: clinical trials

Immunotech Laboratories (IMMB) Patented "IPF" Technology A Serious Contender In The Race For HIV & Cancer Cures
SUNNYVALE, Calif., Feb. 4, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 4, 2013 Category: Pharmaceuticals Source Type: clinical trials

Oncolytics Biotech Inc. Announces Positive REOLSYIN Clinical Trial Data Presented at ASCO Gastrointestinal Cancers Symposium
CALGARY, Jan. 28, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced a poster presentation covering positive preliminary results from a Phase I study examining the intravenous administration of REOLYSIN... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 28, 2013 Category: Pharmaceuticals Source Type: clinical trials

Generex Oral-lyn Phase III Dossier Submitted To Indian Government For Marketing Approval
Phase III Data Demonstrates Effectiveness and Non-inferiority When Compared to Injected Insulin WORCESTER, Mass. and TORONTO, Jan. 23, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 23, 2013 Category: Pharmaceuticals Source Type: clinical trials

Mirna Therapeutics Presents Preclinical Data on Lead Product Candidate MRX34 at Keystone Conference
AUSTIN, Texas--(BUSINESS WIRE)--Jan 23, 2013 - Mirna Therapeutics, Inc., a biotechnology company pioneering microRNA (miRNA) replacement therapies for cancer, announced that new preclinical data from its lead product candidate will be presented this... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 23, 2013 Category: Pharmaceuticals Source Type: clinical trials

Efficiency of PRGF-Endoret in Combination With a Bone Graft in Lateral Sinus Floor Elevation
Condition: Sinus Floor AugmentationInterventions: Device: Bio-Oss; Device: calcium phosphate ceramicSponsors: Fundación Eduardo Anitua; Fundación Eduardo Anitua; Biotechnology Institute IMASDNot yet recruiting - verified January 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2013 Category: Research Source Type: clinical trials

Efficiency of PRGF-Endoret in Combination With a Bone Graft in Lateral Sinus Floor Elevation
Condition: Sinus Floor AugmentationInterventions: Device: Bio-Oss; Device: calcium phosphate ceramicSponsors: Fundación Eduardo Anitua; Fundación Eduardo Anitua; Biotechnology Institute IMASDRecruiting - verified January 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2013 Category: Research Source Type: clinical trials

Amarantus BioScience Announces Biotech Showcase 2013 Corporate Presentation is Available Online
SUNNYVALE, Calif., Jan. 10, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with protein misfolding and apoptosis... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 10, 2013 Category: Pharmaceuticals Source Type: clinical trials

Amarantus BioScience Announces Positive Efficacy Data for MANF in a Nigral Delivery Neurorestoration Animal Model of Parkinson's Disease
SUNNYVALE, Calif., Jan. 9, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with protein misfolding and apoptosis... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 9, 2013 Category: Pharmaceuticals Source Type: clinical trials

Amarantus Bioscience Neurorestoration Animal Data Presentation to be Webcast Live Today from OneMedForum 2013 at 4:40pm Eastern
SUNNYVALE, Calif., Jan. 8, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments for diseases associated with protein misfolding and apoptosis, today announced that Dr.... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 8, 2013 Category: Pharmaceuticals Source Type: clinical trials

Neuralstem President and CEO to Present 2013 Trials Overview at 2013 Biotech Showcase
Updates on Upcoming ALS Phase II - NSI-189 Phase Ib - Stroke Phase I/II in China Live Audio Webcast to Air on Tuesday, January 8, at 3:45 p.m. PT ROCKVILLE, Md., Jan. 4, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 4, 2013 Category: Pharmaceuticals Source Type: clinical trials

Oncolytics Biotech Inc. Announces Positive Top Line REOLYSIN Data for First Endpoint in Randomized Phase III Study in Head and Neck Cancers
CALGARY, Dec. 13, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC) (NASDAQ: ONCY) today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 13, 2012 Category: Pharmaceuticals Source Type: clinical trials

Aduro Announces Two Presentations at Keystone Meeting
BERKELEY, Calif.--(BUSINESS WIRE)--Dec 12, 2012 - Aduro BioTech, Inc. is pleased to announce that Thomas W. Dubensky, Chief Scientific Officer, and Peter Lauer, Director of Molecular Biology, have been selected to deliver oral presentations at... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 12, 2012 Category: Pharmaceuticals Source Type: clinical trials

ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented at ASH
Benefit seen in both lenalidomide-naïve and lenalidomide-refractory multiple myeloma WALTHAM, Mass.--(BUSINESS WIRE)--Dec 10, 2012 - ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops anticancer therapeutics using its... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 10, 2012 Category: Pharmaceuticals Source Type: clinical trials

Sirona Biochem's SGLT Inhibitor Performs Better Than Johnson and Johnson?s SGLT Inhibitor, According to Study
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 10, 2012 Category: Pharmaceuticals Source Type: clinical trials

PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
ATLANTA and NES-ZIONA, Israel, Dec. 7, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present preclinical data on its long-acting clotting Factor VIIa (Factor Vlla-CTP) at the 54th Annual... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 7, 2012 Category: Pharmaceuticals Source Type: clinical trials